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The ULICE project started in 2009 to address two different 
complementary issues: the development of the appropriate 
instruments for hadrontherapy, with emphasis on carbon ion 
therapy, and the need for intensive collaboration among the 
existing and planned centres, as well as with the European 
hadrontherapy community at large. ULICE was funded by the 
European Commission and involved 20 European institutions 
coordinated by CNAO in Pavia. All the existing and planned 
European ion therapy facilities were involved in the project, 
together with two research centres (CERN and GSI) and 
industrial companies. The approach of ULICE to 
hadrontherapy dealed with all its aspects from medical 
physics to radiobiology, from accelerators to particle beams 
in clinics. The experience being built up in Heidelberg (HIT), 
with more than 2000 patients treated, and Pavia with more 
than 500 patients treated, helped the development of 
hadrontherapy in Europe and provided patients throughout 
Europe access to these centres with treatment according to 
standardized protocols. In addition, other centres planned in 
Europe (MedAustron) which are due to start, ware benefit 
from this experience. One of the most relevant results of the 
ULICE project was the establishment of an international 
board – IONTREB International Ion Beam Therapy Research 
Board - focusing on clinical aspects of the hadrontherapy. 
The project consisted of 3 pillars, Joint Research Activities – 
focused on the development of instruments and protocols, 
Networking – to increase cooperation between facilities and 
research communities, and Transnational access – to allow 
access to hadrontherapy facilities to researchers wanting to 
perform radiobiological and physics experiments as well as 
clinical studies. The Joint Research Activities was 
coordinated by the Medical University of Vienna and focused 
on improving the performance of hadrontherapy facilities 
through the development of various instruments. The JRA 
pillar dealed with clinical issues such as developing novel 
adaptive treatment planning, including clinical protocols that 
combine different types of irradiations, and developing a 
computer assisted patient selection program accessible to 
the whole European community; this was not only enable an 
efficient patient referral to the existing facilities, but also 
allow to pursue the clinical research focused on tumours with 
specific biological characteristics and/or critical location. 
These tools provided a research infrastructure producing 
scientifically sound evidence on the efficacy of 
hadrontherapy. Among the technical issues that ULICE will 
address through JRA is the challenge of reducing the 
dimensions and cost of the gantries. The Networking 
Activities pillar was coordinated by CERN and focuses on 
communication, interaction and interdisciplinary discussion 
among the 20 partners and with the external world, and 
dissemination of the project results to the wider community 
involved in cancer care. Networking activities provided the 
external research community with a clear knowledge of what 
is possible and what is needed in terms of research to be 
carried out at the facilities (both through dissemination 
activities, residential training for researchers and through 
scientific events and publications). The Transnational Access 
was coordinated by the University Hospital of Heidelberg, 
and aims at providing access, at HIT and CNAO, for external 
researchers to the ion therapy facilities for preclinical 
research with the available beams of particles. Beam time 
was allocated to the external researchers through a review 
committee, that assessed the scientific impact of the 
proposed research project. The Transnational Access pillar 
also produced agreed protocols for multi centric clinical 
trials, and allowed external researchers to participate in 
these trials. These goals were facilitated making an extensive 
use of advanced e-science grid technology. 
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Radiation therapy represents an important part of 
multimodal cancer therapy in children. Due to increasing 
efficacy of cancer therapy overall treatment outcomes 
considerably improved. Over the last about 50 years the 
situation in childhood malignancies has changed from an 
inevitably fatal condition to one that is potentially curable, 
with overall 5-year survival rates approaching 80%. However, 
it is well understood that growing tissues are particularly 
sensitive to radiation injury. The burden of multimodal 
treatment consisting often of surgery, cytotoxic and radiation 
therapy jeopardizes the future life of the patients. 
Therefore, reduction of late sequelae and improvement of 
quality of life have become a major concern in paediatric 
cancer survivors.  
Proton beam therapy (PT) has become of increasing interest 
in paediatric oncology. Several dosimetric studies clearly 
demonstrated that PT can better limit the irradiated volume 
as compared to photon technique. Therefore, PT is a 
promising method to reduce the risk for acute and late 
effects, especially with regard to paediatric tumors. Over the 
last decades clinical experience in PT in childhood cancer 
was restricted due to limited availability and very few 
facilities being hospital based. So far, prospective approaches 
were missing, cohorts were small and observation times 
short,  especially  with  regard  to  very  young  children  being  
treated with PT. However, the number of children being 
treated with protons for solid tumors is currently increasing 
due to a growing number of proton facilities being in 
operation worldwide. In Europe and US common indications 
for treatment with PT in the paediatric cohort are as well 
local tumors of central nervous system (CNS) (i.e. glioma, 
medulloblastoma, ependymoma, craniopharyngeoma, and 
intracranial germ cell tumors) as non-CNS tumors (i.e. 
chordoma/chondrosarcoma, and rhabdomyosarcoma). 
Treatment results are promising with regard to local control 
rates. Recent data on neurocognitive functioning and quality 
of life seem to confirm favourable outcome after PT. 
Additional, first experiences suggest that secondary cancer 
induction can be reduced when using PT. Still, more clinical 
data will need to emerge and to quantify the clinical benefit 
of PT. Therefore, PT should be established in a prospective 
approach within multimodality cancer concepts to 
ensure optimal treatment and careful future evaluation. 
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Despite late complications related to radiation therapy, RT 
remains a standard component of treatment among pediatric 
patients.                                                                               
The current aim of many pediatric clinical trials is to reduce 
dose and volume of irradiation to decrease side effects 
without affecting the rate of local control using multi-
modality treatment. 
Recent advances in radiotherapy technology contribute also 
to improve therapeutic ratio thanks to better conformal dose 
distribution and avoidance of surrounding critical structures. 
Integration of multimodal imaging in target delineation, use 
of CT for treatment planning (3D conformal radiation 
therapy) and immobilization devices have significantly 
decreased clinical and planning target volume margins. 
Intensity modulated radiation therapy could be particularly 
useful in cases of complex and large volume closed to critical 
structures.  While high dose to neighboring structures can be 
selectively decreased by the means of IMRT, low dose is 
raised in the rest of the body with theoretical increased risk 
of secondary malignancies or unexpected toxicities related to 
irradiation of very sensitive organs at risk located at distance 
of target volume. Number of prospective studies comparing 
IMRT to 3D CRT is low. However available data suggest that 
IMRT provided local control equivalent to 3D CRT with 
favorable short term toxicity profile and reduction of some 
sequelae.  No excess of second tumor is described but follow-
up is still limited.   
Concerning strategies for management of internal target 
movement due to respiratory motion, the more widespread 
modality in pediatric radiotherapy is 4-dimensional CT for 
radiation. Other techniques such as active breathing control 
or respiratory gating is not widely widespread because their 
use is conditioned by collaboration ability and patient age. 
Up to now stereotactic radiation therapy has been mainly 
used in childhood for intracranial benign disease by 
neurosurgeon. However development of non-invasive 
repositioning system and LINAC dedicated to stereotactic 
irradiation gives the opportunity of hypofractionated 
treatment of metastasis or recurrence in previously 
irradiated field with minimal impact of quality of live in 
palliative setting.   
With high precision techniques, reproducibility in daily set-up 
becomes more critical to prevent geographic misses and 
image-guided RT (IGRT) has become a common practice of 
care for children as for the adults. One of the most applied 
IGRT technique is cone-beam computed tomography (CBCT). 
A limitation in use of CBCT among pediatric population is the 
extra dose deposit to critical structures witch is higher in 
children than in adults. Because of potential of yielding a 
secondary cancer at long term, it is essential to adapt 
scanning protocol when CBCT is applied to pediatric cancer 
patients routinely. 
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Neuroblastoma, predominantly a cancer of young children, is 
derived from the sympathetic nervous system. Patients are 
risk-stratified by age, stage and molecular pathology to guide 
treatment and predict outcome. High-risk neuroblastoma, 
usually defined as metastatic disease over the age of one 
year, or the presence of MYCN amplification, is the most 
common risk group, and carries a high mortality. New and 
better treatments are necessary.  
Neuroblastoma cells usually express the Noradrenaline 
Transporter (NAT) molecule which takes up meta-
Iodobenzylguanidine (mIBG), a noradenaline analogue. 
Labelled with iodine-123 for imaging or iodine-131 for 
therapy, mIBG has been used clinically in neuroblastoma and 
other NAT expressing tumours for about 30 years. Semi-
quantitative scoring of 123I-mIBG scintigraphy has become the 
gold standard imaging technique for staging, response 
assessment and follow-up of patients with neuroblastoma. 
Molecular radiotherapy with 131I-mIBG is an attractive 
treatment option for children with high-risk metastatic 
neuroblastoma because (1) the disease is disseminated, 
making local therapies alone inadequate, (2)  123I-mIBG 
scintigraphy is a predictive imaging biomarker for avid 
accumulation of 131I-mIBG in the primary tumour and 
metastatic sites, and (3) neuroblastoma is often relatively 
radiosensitive meaning impressive responses to treatment 
can be seen. 
Initially used in relapsed patients with only palliative intent, 
the use of 131I-mIBG therapy has in recent years has been 
brought forward in the course of the illness as either a first- 
or second-line strategy with the aim of increasing the 
prospects for cure. Further research efforts, especially 
randomised trials, are however needed to demonstrate its 
true value. 
The principal and therefore dose-limiting toxicity of 131I-mIBG 
therapy is haematological. The whole body absorbed 
radiation dose correlates with the haematological toxicity, 
and so whole body dosimetry can be used, in conjunction 
with peripheral blood stem cell support, to allow the use 
of higher administered activities than were previously 
considered safe. There is laboratory evidence to support the 
hypothesis that improvements in outcome may possibly be 
achieved by the simultaneous use of radiosensitising drugs 
such as topoisomerase I inhibitors. Initial clinical experience 
has been published, and clinical trials using irinotecan and 
topotecan in conjunction with 131I-mIBG are in progress or 
planned to evaluate this approach further. 
There are practical challenges when young children need to 
receive high administered activities of 131I-mIBG. The use of 
comforters and carers, usually the child's parents, is an 
essential addition to medical and nursing care. All individuals 
involved need to appreciate the risks, and be trained in 
sensible radiation protection precautions. 
Other forms of molecular radiotherapy for neuroblastoma are 
being investigated, particularly peptide receptor radionuclide 
therapy targeting the somatostatin receptor, using 
radiolabelled somatostatin analogues. Examples are 90Y-
DOTATOC and 177Lu-DOTATATE. These are not necessarily 
alternatives to 131I-mIBG therapy. Both immunohistochemical 
studies of NAT and somatostatin receptor expression in 
neuroblastoma tissue, and imaging comparisons of 123I-mIBG 
scintigraphy and 68Ga-DOTATATE PET/CT demonstrate a 
heterogeneity of appearances suggesting that they may be 
complementary. 
This presentation reviews the published evidence in relation 
to 131I-mIBG therapy for neuroblastoma, and describes the 
plans to further evaluate its place through clinical trials in 
the context of other systemic treatments for this hard-to-
cure disease. 
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